Boris Engels PhD
Senior Scientific Director for Gene-Engineered T Cell Therapies, Miltenyi Biotec B.V. & Co. KG
With expertise in cancer immunology, he leads teams advancing CAR- and TCR-redirected T cells for life-threatening diseases.
Previously at Novartis, he developed cell therapies, and at the University of Chicago, he explored TCR interactions. He holds a Ph.D. in biology from the Max-Delbrück Centre for Molecular Medicine, Berlin.